Osteoporosis International

, Volume 14, Issue 12, pp 1013–1019

Beneficial treatment with risedronate in long-term survivors after allogeneic stem cell transplantation for hematological malignancies

  • L. Tauchmanovà
  • C. Selleri
  • M. Esposito
  • C. Di Somma
  • F. OrioJr.
  • G. Bifulco
  • S. Palomba
  • G. Lombardi
  • B. Rotoli
  • A. Colao
Original Article

DOI: 10.1007/s00198-003-1520-2

Cite this article as:
Tauchmanovà, L., Selleri, C., Esposito, M. et al. Osteoporos Int (2003) 14: 1013. doi:10.1007/s00198-003-1520-2

Abstract

In this prospective randomized study we evaluated the effect of risedronate, an aminobisphosphonate, on bone mass and turnover in patients who had undergone allogeneic stem cell transplant (SCT) for hematological malignancies. Thirty-four patients (18 females, 16 males, age 32±10 years) with bone mineral density (BMD) ≤−1.5 SD as a T-score at least 6 months after SCT were treated with calcium 1 g/day and vitamin D 800 IU/day and randomized to receive (n=17, group 1) or not receive (n=17, group 2) oral risedronate 5 mg/day. The duration of treatment was 12 months. After 6 months, lumbar BMD increased by 4.4±1.6% in patients of group 1 and decreased by 4.3±1.5% in those of group 2 (P<0.05); at the femoral neck, BMD did not change significantly in patients of group 1 (+1.2±1.2%), while it decreased in those of group 2 (−4.3±2.1%; P<0.05). After 12 months, lumbar BMD further increased (+5.9±1.7%, P<0.05), compared to baseline in group 1 and slightly increased (+1.1±1.4%) in group 2. No further changes were observed at femoral neck in both groups. In conclusion, treatment with risedronate for 12 months increased BMD significantly at the lumbar spine and prevented further bone loss at the femoral neck in long-term survivors after allo-SCT.

Keywords

Allogeneic stem cell transplant DEXA Osteocalcin Osteoporosis Risedronate 

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2003

Authors and Affiliations

  • L. Tauchmanovà
    • 1
  • C. Selleri
    • 2
  • M. Esposito
    • 2
  • C. Di Somma
    • 1
  • F. OrioJr.
    • 1
  • G. Bifulco
    • 3
  • S. Palomba
    • 4
  • G. Lombardi
    • 1
  • B. Rotoli
    • 2
  • A. Colao
    • 1
  1. 1.Department of Molecular and Clinical Endocrinology and OncologyUniversity Federico II of NaplesNaplesItaly
  2. 2.Division of HematologyUniversity Federico II of NaplesNaplesItaly
  3. 3.Department of Gynecology and ObstetricsUniversity Federico II of NaplesNaplesItaly
  4. 4.Department of Gynecology and ObstetricsUniversity of Catanzaro “Magna Graecia”CatanzaroItaly

Personalised recommendations